Insulin-like growth factors (IGF) are critical for normal intrauterine and childhood growth and sustaining health throughout life. We showed previously that production of IGF-I and -II requires interaction with the chaperone Glucose Regulated Protein 94 (GRP94) and that the amount of secreted IGFs is proportional to the GRP94 activity. Therefore, we tested the hypothesis that functional polymorphisms of human GRP94 affect IGF production and thereby human health. We describe a hypomorphic variant of human GRP94, P300L, whose heterozygous carriers have 9% lower circulating IGF-I concentration. P300L was found first in a child with primary IGF deficiency, and later shown to be a non-common SNP with frequencies of 1-4% in various populations. When tested in the grp94 -/-cell-based complementation assay, P300L supported only ϳ58% of IGF secretion relative to wild type GRP94. Furthermore, recombinant P300L showed impaired nucleotide binding activity. These in vitro data strongly support a causal relationship between the GRP94 variant and the decreased concentration of circulating IGF-I, as observed in human carriers of P300L. Thus, mutations in GRP94 that affect its IGF-chaperone activity represent a novel causal genetic mechanism that limits IGF biosynthesis, quite a distinct mechanism from the known genes in the growth hormone/IGF signaling network.
Insulin-like growth factors (IGF) are critical for normal intrauterine and childhood growth and sustaining health throughout life. We showed previously that production of IGF-I and -II requires interaction with the chaperone Glucose Regulated Protein 94 (GRP94) and that the amount of secreted IGFs is proportional to the GRP94 activity. Therefore, we tested the hypothesis that functional polymorphisms of human GRP94 affect IGF production and thereby human health. We describe a hypomorphic variant of human GRP94, P300L, whose heterozygous carriers have 9% lower circulating IGF-I concentration. P300L was found first in a child with primary IGF deficiency, and later shown to be a non-common SNP with frequencies of 1-4% in various populations. When tested in the grp94 -/-cell-based complementation assay, P300L supported only ϳ58% of IGF secretion relative to wild type GRP94. Furthermore, recombinant P300L showed impaired nucleotide binding activity. These in vitro data strongly support a causal relationship between the GRP94 variant and the decreased concentration of circulating IGF-I, as observed in human carriers of P300L. Thus, mutations in GRP94 that affect its IGF-chaperone activity represent a novel causal genetic mechanism that limits IGF biosynthesis, quite a distinct mechanism from the known genes in the growth hormone/IGF signaling network.
G
lucose-regulated protein 94 (GRP94) is a ubiquitously expressed endoplasmic reticulum (ER)-resident chaperone that is essential for growth and development of multicellular organisms (1) (2) (3) (4) . It is a unique chaperone in being selective towards a small subset of membrane and secreted proteins. GRP94 client proteins include immunogloblins (5) , ␤1 integrins (6), glycoprotein Ib-IX-V complex (7), Toll-like receptors 2,4,5,7,9 (8) and, most importantly for this study, insulin-like growth factor (IGF)-I and -II (1, 9) . The presence of GRP94 and its intact ATPase activity are prerequisites for proper IGF-I/II folding, and cannot be substituted by other chaperones (2, 9) . Consequently, variability in GRP94 activity impacts IGF-I/II production.
The ATPase activity of GRP94 requires not only the nucleotide binding pocket in the GRP94 N-terminal domain, but also the second, acidic domain (residues 265-344) that follows (10) , as well as residues in the middle domain of the protein (11) . Site-directed mutations in these domains affect the ATPase and chaperone activities of GRP94 (9), as we have previously shown by biochemical and cell-based assays (12) . Therefore, sequence variability in several domains of GRP94 affects its function and may have phenotypic consequences.
Since grp94ϩ/-mice have no detectable phenotype, half of GRP94 expression level or activity is sufficient for normal development. However, reducing the total GRP94 activity below 50% leads to multiple defects (1) . Interestingly, inhibition or knock-down of GRP94 does not cause an unfolded protein response as would be the case for other ER chaperones, but rather leads to a limited upregulation of specific genes such as immunoglobulin binding protein (BiP) and protein disulfide isomerase A6 (PDIA6) (13) . These observations support the substrate selectivity of GRP94.
Of all the known substrates, IGFs depend most stringently on GRP94, as shown in cell culture and in animal models (4, 9) . The interaction of GRP94 with IGF-I/II is direct, transient and specific; distinct pro-IGF intermediates bind to GRP94 after synthesis, while mature IGFs dissociate from GRP94 (9) . We created a muscle-specific GRP94 KO that resulted in dramatic reduction of locally produced IGF-I, 30% reduction in circulating IGF-I concentration, small muscle mass, and a whole body growth phenotype (4) . These studies demonstrate the biological importance of the GRP94-IGF interaction.
The mammalian IGF system consists of two homologous hormones (IGF-I and -II) that bind to type 1 IGF receptors (IGF1R), insulin receptors (IR) or hybrid IR/ IGF1R receptors (14) . Receptor activation initiates signaling pathways that regulate growth and survival at the cellular and organismal levels (15) (16) (17) (18) . Expression of IGF-I itself is linked to growth hormone (GH) signaling through a feedback loop (19 -21) . Many monogenic disorders that lead to perturbations in growth have been identified (22) , including mutations that affect members of the GH/IGF axis and modulate activity of the system. Among the known ones are mutations in the genes that code for GH releasing hormone and its receptor (23) (24) (25) , GH itself (26) , GH receptor (27, 28) , STAT5b (29) , IGF-I (30 -32), IGF1R (33, 34) and the acid-labile subunit protein (IG-FALS gene), which forms a circulating complex with IGF-I (35) .
So far, human GRP94 variants have not been reported to play a role in GH/IGF-I axis modulation nor in the context of any other growth phenotype. Nonetheless, the experimental evidence from animal models and cell culture studies (1, 2, 4, 9) Leucine (P300L) . In vitro, this variant shows 42% diminished activity in support of IGF-II production. Purified recombinant P300L variant showed impaired nucleotide binding and subtle changes in the protein structure. The P300L variant affects circulating IGF-I levels and height of even heterozygous adult carriers. Therefore, we have identified the first hypomorphic variant of GRP94 and relate it to a specific IGF-I phenotype in humans.
Materials and Methods

GRP94 sequence analysis
Genomic DNA was collected for sequencing of the HSP90B1 gene (encoding GRP94) from 9 subjects enrolled in the PIGFD Consortium in whom mutations in candidate genes for IGF-I, IGF1R, GH receptor or STAT5B had already been excluded (36) . The PIGFD Consortium is an international registry of patients with growth failure (defined as height Ͻ-2.0 SDS) and unexplained PIGFD (circulating IGF-I levels Ͻ-3.0 SDS) who consented to provide DNA for genetic studies. Additionally, we obtained DNA of 7 subjects from the Leiden University Medical Center (LUMC) cohort where patients presented with apparent GH insensitivity based on variably low height and IGF-I, yet normal GH secretion (37) . Eighteen exons of the gene were PCR amplified from genomic DNA (1-10ng per run) using 8 pairs of primers and GoTaq Hot Start Green Mix (Promega Madison, WI) according to manufacturer's protocol. The resulting mixture was purified and sequenced. For probe design and sequences see Supplementary Data file.
Exon sequence variants resulting in altered protein structure were investigated further by in vitro functional studies as described below. Sequencing of the HSP90B1 gene from the parents of identified probands was also conducted to determine whether the variant had been inherited or represented a de novo mutation. Of note, the amino acid numbering used in the work corresponds to the mature GRP94 protein sequence, thus 21 should be added to any residue numbered based on the gene sequence.
The prevalence of identified mutations was determined using public domain databases, including the National Center for Biotechnology Information dbSNP and NHLBI Exome Sequencing Project (ESP) Exome Variant Server and the Exome Aggregation Consortium (ExAC, Cambridge, MA).
Plasmids and site-directed mutagenesis
The cDNA for canine GRP94 was cloned into pCDNA3.1 with eF1␣ promoter and fused after codon 777 to monomeric Green or Cherry fluorescent proteins ending with a KDEL Cterminal sequence as in (12) . Site-directed mutagenesis (Quikchange, Stratagene La Jolla, CA) was used to generate all point mutants described. The primers used in mutagenesis are detailed in Supplemental Methods. Canine and human GRP94 have 98% sequence identity and the canine GRP94 expression complements several of features of human or murine GRP94-deficient cells (2, 12, 13) Cell culture
Grp94
-/-mouse embryonic fibroblast (MEF) lines were described previously [1] . They were maintained on fibronectincoated plates in endotoxin-free DMEM (Gibco/Life Technologies, Grand Island, NY), supplemented with penicillin (100 Units/mL), streptomycin (100 g/mL), L-glutamine, (2.92 mg/ mL), sodium pyruvate, nonessential amino acids and ESGRO® (Chemicon International, Temecula, CA), and 10% fetal bovine serum (FBS, HyClone, Thermo Scientific, South Logan, UT). HEK293T cells were maintained in DMEM supplemented with antibiotics and 10% FBS (Atlanta Biologicals, Lawrenceville, GA).
IGF-dependent cell survival assay
This cell survival assay uses grp94 -/-MEFs, which in the absence of active GRP94 cannot produce endogenous IGF-II and therefore cannot survive growth in low serum. The assay and its validation were performed as described in (9) and (12) . Briefly, 2 ϫ 10 5 grp94 -/-MEFs 18h after plating were transfected with plasmids coding for wild type (WT) or variants of canine GRP94-GFP, using Lipofectamine 2000 (Life Technologies, Grand Island, NY). After subsequent growth for 30h, the cells were washed twice in serum-free medium and incubated in the absence of serum for up to 39h. Where specified, 300 or 900 pg/mL of murine IGF-II (RD Systems, Minneapolis, MN) was added to the media. At the indicated times, cells were washed and photographed (15 pictures per sample). GRP94-positive cells were counted, and the changes in their numbers as a function of time were calculated. The survival index of cells expressing WT or GRP94 variants (12) was calculated at the time point within each experiment where survival of the cells expressing GRP94 was one-tenth the survival of the cells expressing WT GRP94. More experimental details are provided in Supplemental Methods.
Recombinant N34 -355 GRP94
The truncated, His-tagged mouse GRP94 containing the Nterminal half of the protein (residues 34 -355) was expressed in E. coli, and purified by affinity chromatography as described in (38) . This recombinant protein retains the peptide binding and calcium binding activities of the apo-protein, as well as the epitope for the conformation-sensitive antibody 9G10 (39) .
Determination of ATP binding
His-tagged N34 -355 GRP94 WT, E82A or P300L recombinant proteins were incubated with ␥-phosphate-linked ATP resin (gift of Dr. Timothy Haystead, Duke University) as described previously (40) . In separate experiments, preformed complexes of GRP94 and the ATP resin were incubated with 0 -40 M concentrations of ATP (Sigma-Aldrich, St. Luis, MO) for additional 3h at 4°C to allow for dissociation. Samples were then subjected to SDS-PAGE and immunoblotting as described above, and the fraction of GRP94 bound to the ATP resin was quantified.
Assessment of GRP94 conformation by antibody 9G10
The monoclonal antibody 9G10 recognizes an epitope within the second domain of GRP94 which changes its conformation when the protein binds nucleotides via its first domain (39) . Therefore, reactivity with 9G10 provides a convenient assay for GRP94 conformation. A solid-phase indirect binding assay was used (see Supplemental Methods) and of 9G10 bound to GRP94 epitope quantified with an Odyssey scanner at 680nm. Specificity was ensured by inhibition with the GRP94 inhibitor radicicol.
Intracellular localization of GRP94 variants
Grp94
-/-MEFs were transiently transfected with plasmids coding for ER-targeted GFP, cherry-tagged WT GRP94 and GFP-tagged P300L GRP94. Cells were fixed 24h post-transfection and processed for imaging, as described in Supplemental Methods.
Human populations used:
I. Leiden cohort of short-stature children Subjects were selected from a previously described cohort with apparent GH insensitivity based on variably low height and low IGF-I SDS (37) . All had normal GH secretion.
II. Health In Men Study (HIMS; Australia)
This study enrolled only older Caucasian males, aged 70 to 89 years, from Perth, Australia, and thus includes a relatively homogenous population. Detailed description of this cohort has been published previously (41, 42) .
HSP90B1 was genotyped from 3862 subjects using custom designed probes for TaqMan SNP Genotyping Assay from (Life Technologies) (see supplementary material). For measurement of total IGF-I, samples were pretreated with acid to displace IGF-I from its binding proteins, followed by neutralization and addition of binding inhibitors prior to measurement using the DSL-10 -2800 kit (Diagnostic Systems Laboratories, Inc., Webster, TX). Blood concentrations of IGF-I and IGF binding protein-3 (IGFBP-3) were measured using DSL-10 -2800 and DSL-10 -6600 kits, respectively, per manufacturer's protocols (both from Diagnostic Systems Laboratories, Inc., Webster, TX).
IGF-I was measured in 98 carriers of P300L, 3568 controls and the homozygous P300L subject. The measurements employed one standardized technique (ELISA as described above) in the same clinical laboratory and were made during the span of only 3 months. These factors helped limit the variability in reported IGF-I levels.
III. Longevity Genes Project (New York)
The Longevity Genes Project (LGP) is a large prospective cohort study based in Albert Einstein College of Medicine, New York (43) . The project consists of Ashkenazi Jewish probands with exceptional longevity (mean age 98.2 years), their offspring (mean age 68.3 years), and a control group age-matched to the offspring. HSP90B1 sequencing was performed on 459 cases (probands and their offspring) and 1807 controls. IGF-I concentration was measured using DSL-10 -2800 kit as above.
IV. Danish Cohort Study
This cohort included 15 663 subjects from Denmark from five combined studies, described previously (44) . In brief, the cohort is based on the general Danish population where roughly half of the subjects were diagnosed with type 2 diabetes. Every subject was genotyped for 16 192 SNPs while whole exome sequencing was performed on a subset of 2000 subjects. Height data were available in this population, but IGF-I was not measured.
V. Health, Aging, and Body Composition Study (HABC)
We sequenced 100 cases from the NIA HABC cohort (http:// www.grc.nia.nih.gov/branches/leps/healthabc/) with IGF-I data available. The study population consisted of 3075 persons age 70 -79 at baseline with about equal numbers of men and women. We selected three sample groups with circulating IGF-1 levels below 57ng/ml, between 66 -100ng/ml and over 200ng/ml.
Statistics
For normally distributed continuous variables, Means (ϮSD) were compared between P300L carriers and controls using independent samples t-tests. In contrast, non-normally distributed data were summarized as median (interquartile range) and compared using nonparametric (Mann Whitney U) test. Extremely high IGF-I values in an elderly population may represent pathology (ie, acromegaly) or laboratory errors (eg, assay artifact from IGFBP interference) (45) . For this reason, all IGF-I measurements above ϩ3 SD from the mean (above 315.5 ng/ml) were excluded as biologically implausible from the HIMS study (26 wild type, 2 P300L carriers). Data were analyzed using SPSS version 22.0 (IBM, New York USA).
Other methods
Immunoblotting, antibodies, GRP94 and murine IGF-II ELISA, immunofluorescence techniques, Circular Dichroism measurements and software used for alignment of sequences and prediction of structure are described in Supplemental Methods.
Results
GRP94 analysis in patients with primary IGF deficiency
We sequenced the HSP90B1 (grp94) gene from children diagnosed with PIGFD, 9 from the cohort of the PIGFD Consortium and 7 from LUMC cohort (37) . One subject, a male with in utero growth retardation, postnatal growth failure and nondetectable circulating IGF-I at age 4 months ( Figure 1A ), was found to be heterozygous at chromosome 12 position 103 938 446 (GRCh38), with a C to T substitution in one allele and a wild type sequence in the other ( Figure 1B ). This substitution changed the amino acid coding sequence from Proline 300 to Leucine (note, our numbering system assigned 1 to the N-terminal Asparagine created after cleavage of the signal sequence, to align with the mature protein sequence, rather than to the initiating Methionine, as is the convention in genomics. Therefore, P300 in this paper is identical to P321 in genomic databases). The patient's mother also carried this mutation and had a height in the lower half of the reference population (height -0.9 SD) ( Figure 1B) . Her circulating IGF-I concentration was not available.
To determine if P300L was a unique mutation, we interrogated several public-domain databases with GRP94 sequences. We found that P300L was a minor allele frequency variant (rs116891695) that occurs in several human cohorts with frequencies ranging from 0.8% (African population, ESP-AA, Table 1 ) to 4% (Danish population, D15K, Table 1 ). In every case that P300 was substituted (n ϭ 2319), it was changed into Leucine and not to another amino acid, even though a single base change can convert Proline to five amino acids other than Leucine.
In vitro analysis of the effects of the P300L mutation on GRP94 function
P300L is hypomorphic in supporting IGF-II production
Since the P300L variant was initially found in an PIGFD patient we sought to determine its functionality in supporting IGF-I production. The best in vitro system available is expression of the variant in grp94 -/-mouse embryonic fibroblasts (MEFs) (9) . These cells produce IGF-II, but our previous work showed that IGF-I is regulated by GRP94 variants in the same manner as IGF-II (2, 4). Expression of GFP-tagged P300L GRP94 in knockout MEFs showed reticular localization that overlapped with that of cherry-tagged wild type (WT) GRP94 (Figure 2A ), as expected from an ER resident protein. When grp94 -/-MEFs, transfected with various forms of GRP94, were analyzed by western blots, expression levels of P300L were similar to WT and the E82A mutant (impaired in ATP hydrolysis, (2)) and higher than that of the triple point mutant E82A/ D128N/G132A (impaired in both ATP binding and hydrolysis; Figure 2B ). Therefore, P300L exhibits normal cellular localization and is stably expressed with levels similar to WT GRP94.
To test the functionality of P300L variant we used the previously described cell-based assay (9) , where the survival of serum-starved grp94 -/-MEFs relies on their ability to produce and secrete IGF-II. Grp94 -/-MEFs were transiently transfected with WT, P300L, E82A or E82A/ D128N/G132A, GFP-tagged GRP94. 28h later, cells were serum-starved and at the indicated time points images of GFP-positive cells were captured ( Figure 2C ) and scored ( Figure 2D ). Cells expressing WT GRP94 survived longer (more GFP-positive cells at different time points) than cells expressing the completely inactive GRP94, E82A/D128N/ G132A variant, all of which died within 25h. The point mutant E82A had some residual activity ( Figure 2D -E), consistent with our previous results (12) , and P300L was clearly more active than E82A but consistently less so than WT GRP94. The calculated survival index of GFP-positive cells, representing the functionality of the tested GRP94 variants (Figure 2E ), was 58% of wild type for the P300L variant (P Ͻ .01). Coexpression of the P300L variant with WT GRP94 in the same cells did not diminish cell survival, indicating that P300L does not act in dominant negative fashion. Thus, we conclude that P300L is a hypomorphic mutant of GRP94.
Survival of serum-deprived grp94 -/-MEFs depends greatly on their ability to secrete mIGF-II. We first estimated the levels of recombinant mIGF-II necessary to rescue grp94 -/-MEFs from apoptosis. The cells were transfected with WT GRP94 or nonactive Kpn deletion mutant (12) alone or Kpn-transfected cells were supplemented with 300 or 900 pg/mL of mouse IGF-II. Addition of the lower dose of mIGF-II rescued cell survival partially, whereas increasing it just 3-fold was sufficient to provide a rescue similar to that achieved by WT GRP94 and to alter the cells' fate during the starvation period (Suppl. Figure  1A) . Therefore, using the same experimental approach, where grp94 -/-MEFs were transiently transfected with variants of GRP94 and subsequently stressed by serum withdrawal, we quantified the concentration of mIGF-II secreted over the span of the 16 hours starvation. grp94 -/-MEFs that were not transfected, or were transfected with inactive variants of GRP94, produced similar mIGF-II concentrations of 85 pg/mL. Cells transfected with WT and P300L variants, secreted 141 and 118 pg/mL of mIGF-II, respectively ( Figure 2F ). Assuming the signal detected from nontransfected cells represents "leakage" of intracellular, inactive mIGF-II from dying cells, which cannot support growth of IGF-dependent cells, the P300L variant supported ϳ58% of IGF-II secretion relative to WT GRP94. The difference in the amount of secreted mIGF-II seems to be sufficient to dictate survival or death of the cells in the cell-based assay (see also (12) ).
The P300L mutation is predicted to impact the structure of GRP94 Pro300 is an evolutionarily conserved residue ( Figure  3A ) located in the second, charged linker domain of GRP94. This domain is absent from the previously determined crystal structures of GRP94 (46, 47) making it difficult to predict the structural effect of the specific substi-
press.endocrine.org/journal/endotution. We therefore used two computational predictions (Phyre2 and PSIPRED; Figure 3B ) and inferred that Pro300 is flanked by two ␣ helices and its substitution with Leucine or any other amino acid, may cause 'fusion' of the two helices into one 25 residue-long ␣ helix ( Figure 3B ). Previous studies showed that deletion of the linker domain (amino acids 280 -345) impacted the nucleotide-binding pocket of GRP94 (10) , and the generation of a long ␣ helix by P300L may similarly affect the nucleotide binding of GRP94.
When functional aspects of P300L substitution were analyzed by SIFT and PolyPhen, both algorithms pre- Figure 2 . P300L GRP94 is properly expressed but less effective than WT GRP94 in supporting production of IGF-II. (A) Fluorescence microscopy analysis of expression and intracellular localization of GRP94 in grp94 -/-cells. WT GRP94 mCherry-tagged was coexpressed with P300L GRP94 mGFP-tagged. Cells were fixed after 24 hours and imaged with a 60x objective (n ϭ 2). Bar, 5 m. (B) Comparative expression of GFP-tagged WT GRP94 or P300L, E82A, E82A/D128N /G132A mutants of GRP94. HEK293T cells were harvested 24 hours after transfection with plasmids coding for empty vector (EV) or the indicated GRP94 constructs, and protein extracts were analyzed by immunoblotting with the anti-GRP94 antibody. The lanes were run on the same gel but were noncontiguous. Quantitation of expression levels of exogenous GRP94 as compared to endogenous GRP94 is provided below lanes (n ϭ 2). (C -E) Differential ability of GRP94 mutants to support IGF-II-mediated cell survival. Grp94
-/-MEFs were transiently transfected with a plasmid expressing GFP-tagged WT, P300L, E82A, or E82A/D128N/G132A variants of GRP94. 28h later, cell cultures were serum starved and scored at the indicated intervals by microscopy. C, Pictures of GRP94 expressing cells acquired at the indicated time points from a representative experiment. D, The number of GFP-positive cells was counted at given time points from 15 separate fields. The cell counts were plotted as a percentage of the initial time point (representative experiment shown). E, Activity of GRP94 was calculated as survival index of cells expressing GRP94 mutants. The index was calculated at the time point within each experiment where survival of the cells transfected with E82A/D128N/G132A GRP94 mutant was one-tenth the value of the WT-transfected cells (WT, E82A, E82A/D128N/G132A n ϭ 8, P300L n ϭ 5). Means and standard deviations are graphed. (F) ELISA measurements of IGF-II in supernatants of grp94 -/-cells, 16h after serum withdrawal.
Grp94
-/-MEFs were prepared as in (C) and secreted the indicated levels of IGF-II in the absence of serum. The detection limit of this assay is ϳ60 pg/mL. Means and standard deviations are shown for 2 independent experiments. dicted that Pro300 substitution to most amino acids (with exceptions of P300E and P300K) has 0.995 probability of being damaging to protein function. Interestingly, a P300K substitution, predicted to be "tolerable" (functionally neutral) by SIFT would generate (like P300L) one 25 residue-long helix ( Figure 3B ) raising the possibility that P300L is actually on the spectrum of "tolerable" rather than fully damaging substitutions, a characteristic one would expect from a rare population variant. press.endocrine.org/journal/endo 7 P300L reduces the structural response of GRP94 to Radicicol binding and changes the tertiary structure of GRP94 Secondary structure of native N34 -355 WT and P300L GRP94 was measured by far-UV Circular Dichroism (CD; Figure 3C ). The average content of ␣ helix was 23% and ␤ sheet 7% (as analyzed by SELOCON 3) and did not differ between WT and P300L ( Figure 3C ). However, when GRP94 was incubated for 4 hours in 4°C with 5 M of Radicicol, a small molecule GRP94 inhibitor that binds at its ATP pocket, a bigger decrease in ␣ helix content was observed in WT (2.8%, P ϭ .01) than in P300L variant (1.8%, P ϭ .74; Figure 3D -E). It is important to note that the result may not represent changes in the percentage of ␣ helices, but rather reflect their different packing against other secondary structure elements in the core of GRP94. Such a difference in the magnitude of structural changes upon inhibitor binding may reflect reduced flexibility of the linker domain of P300L and/or lower affinity for Radicicol as compared to WT GRP94.
The near-UV CD measurements of native N34 -355 P300L showed that this protein folded to a defined structure resembling that of WT GRP94. Compared to WT, there was decreased signal at the wavelengths corresponding to the aromatic residues tyrosine and tryptophan. However, this was not due to a global loss of tertiary structure as shown by the spectra of heat-treated or acidtreated samples ( Figure 3F-G) . Rather, this change suggests subtle tertiary structure changes in P300L (p-values for WT/P300L changes were 0.75 for 260nm, 0.03 for 280nm, and 0.04 for 290nm).
The P300L variant affects the nucleotide binding function of GRP94
To test the predicted effects of structural changes in P300L, we used in vitro assays for recombinant GRP94 function. It was previously shown that a truncated WT GRP94 containing amino acids 34 -355 had retained the nucleotide binding activities and could be inhibited by nucleotide mimetics (48) . First, we established that 10 g of His-tagged, N34 -355 GRP94 is sufficient to saturate 15 L of ␥-linked ATP resin beads (Dr. T. Haystead, Duke Univ.; Suppl. Figure 1B) (40) and then we measured the relative ATP-binding capacities of point mutants of recombinant GRP94. As shown in Figure 4A and B, P300L was able to bind ␥-linked ATP beads but only 75% the amount of WT GRP94, and its diminished binding was similar to that of the mutant E82A (82%). In addition to the on-rate of binding, we estimated the off-rate by charging the ATP beads with each GRP94 variant and then eluting the bound proteins with increasing concentrations of free ATP. WT GRP94 was eluted by free ATP more readily than P300L, while the nonhydrolyzing mutant E82A showed only minimal elution ( Figure 4C and D) . In summary, these data show that P300L has a negative impact on the ability of the ATP pocket to bind and release ATP, a biochemical activity that is essential for the chaperone function of GRP94 (12) .
Ligand induced conformational change is diminished in P300L variant
As reported previously (48), GRP94 undergoes structural changes in response to ligand binding. When the inhibitor Radicicol binds to the nucleotide-binding pocket of GRP94, the epitope recognized by the monoclonal antibody 9G10, some 200 amino acids away from the nucleotide-binding pocket, is altered, precluding the binding of 9G10 (48) . We adapted this procedure and covered Ni-plates with equal amounts of His-tagged GRP94 variants. The variants were then incubated with increasing concentrations of Radicicol, and after 4h were probed with the 9G10 antibody. As shown in Figure 4E -F, WT, P300L and E82A GRP94 were recognized by 9G10 with the same efficiency. However, the loss of antibody binding in WT GRP94 was observed with concentrations of Radicicol as low as 0.1 M, while a 100-fold higher concentration of Radicicol was needed for the P300L or E82A proteins. Thus, P300L variant is partially refractory to Radicicol binding and to the conformational change that is reported by loss of the 9G10 epitope.
Assessing the impact of P300L in humans
To assess the impact of P300L on human physiology we analyzed four human populations. First, we sequenced 200 GRP94 alleles from the National Institute of Aging Health ABC cohort, but none contained the P300L substitution. This is possibly due to the high prevalence of African American subjects, where the minor allele frequency is lower (Table 1) .
Second, we genotyped the Health In Men Study cohort (49) , to assess whether carriers of P300L have lower circulating levels of IGF-I. This cohort had a narrow age distribution and a sufficient number of circulating IGF-I measurements to allow meaningful statistical analyses. Among 3862 genotyped cases, 112 subjects (2.9%) were heterozygous for P300L, one was homozygous for this mutation (0.03%) and 3619 (97.07%) were homozygous for wild type GRP94. IGF-I was measured in 98 carriers of P300L, 3568 controls and the homozygous subject. IGF-I concentrations were not normally distributed within these groups. The median (IQR) IGF-I concentration in heterozygous P300L carriers was 120 ng/ml (91-165) and in the noncarriers, 134 ng/ml (101-172) ( Table 2 ; P ϭ .037, Mann Whitney U test). Unlike circulating IGF-I con-centration, there was no significant difference between P300L carriers and subjects with wild type GRP94 in: circulating IGFBP-3 concentration, height, body mass index (BMI) or age ( Table 2) . Except for IGF-I, all other measurements in this cohort were distributed normally. Therefore, consistent with our hypothesis, heterozygous carriers of P300L (n ϭ 98) had a decrease of ϳ10% in serum IGF-I levels, as compared to WT subjects (n ϭ 3568). Given the large variability in IGF-I measurements (50) and the multitude of factors that influence circulating IGF-I levels in vivo, we were impressed that a decrease of 10% could be found with a large enough sample size. press.endocrine.org/journal/endo 9
The relation between P300L and circulating IGF-I was also analyzed in the Longevity Genes Project (Albert Einstein College of Medicine, NY). 34 P300L carriers were found, but IGF-I measurements were available for only 10 of them. This small sample did not enable assessment of the impact of P300L on IGF-I production. However, height data were available in this cohort, and height is often correlated with circulating IGF-I (51). Indeed, when P300L carriers were compared to noncarriers, their mean height was lower, consistent with the hypothesis (Table 3) . The lower height was statistically significant in females and was just below the significance level in males, though the trend was also consistent with the hypothesis.
The fourth population analyzed was the Danish 15K cohort. Among the 7681 male subjects, 299 were carriers of P300L and four were homozygous, but no IGF-I/-II levels had been measured in this cohort. There was also no difference in heights between the P300L carriers and noncarriers in this cohort, in either males (177.7 Ϯ 7.1 cm, n ϭ 299 vs. 177.7 Ϯ 6.9 cm, n ϭ 7687) or females (165.8 Ϯ 6.7 cm, n ϭ 320 vs. 165.0 Ϯ 6.5 cm, n ϭ 7357).
Discussion
This work shows that hypomorphic variants of the chaperone GRP94 exist in humans and that such variants affect circulating levels of IGF-I. Specifically, we used a cellbased complementation assay (12) to show that the human variant P300L supports IGF production less efficiently than wild type GRP94. P300L GRP94 is expressed properly in the endoplasmic reticulum and at levels comparable to wild type GRP94, but has lower chaperone activity towards IGF-II. This lower activity is explained by three molecular differences: 1) Altered ATP binding and dissociation of P300L GRP94, implying reduced ATPase activity; 2) a smaller conformational change induced by ligand binding to GRP94, and 3) an altered global tertiary structure of the variant protein compared to wild type GRP94.
The P300L substitution occurs in the second domain of GRP94, which is an acidic domain that links the N-terminal domain (NTD) with the middle domain. This acidic linker domain is conformationally sensitive: it does not crystalize with the rest of the protein (47) , it contains the epitope for a conformation-sensitive monoclonal antibody 9G10 (39) , and it also contains 1-2 calcium binding sites whose occupancy affects the binding activity of the protein (38) . We presume that the helix-breaking nature of Proline 300 is required for one or more of these conformational aspects and that a Leucine substitution disrupts the conformation, as we see in the circular dichroism and nucleotide binding experiments. This interpretation is consistent with the fact that Proline 300 is substituted only with Leucine and not another amino acid. Presumably, even though Leucine 300 is disruptive, it is not as deleterious as other substitutions.
The P300L variant was reported recently by both the 1000 Genome project and the Exome Aggregation Consortium (http://exac.broadinstitute.org; Accessed May, 2015). P300L is a minor allele frequency (MAF, rs116891695) variant found in 0.8% of Africans and up to 4% of Caucasians. Interestingly, all but two of the approximately 200 nonsynonymous variants in the human HSP90B1 gene are found only in single cases. The two exceptions are P300L and DelE770 (rs5800607; an inframe, single amino acid deletion present in up to 26% of human population). So far, P300L is the only GRP94 variant with associated phenotypic data.
Pro300 is evolutionary conserved in all tested organisms with the exception of C. elegans and is located within the second domain of GRP94, the charged linker domain. This domain is essential for the activity of GRP94, because it mediates a conformational change that is required for the ATPase activity of GRP94 (10, 48, 52) . The structure of this domain cannot be resolved by crystallography (47) , so structural inferences must rely on indirect methods. One method is binding of 9G10, an anti-GRP94 monoclonal antibody, which binds to the linker domain when the nucleotide-binding N-terminal domain is available (10, 48) . As shown in this work, Leu300 does not impact the binding of this conformation-sensitive antibody. Another indirect method is binding of calcium: the E/D-rich sequence within the linker domain contains 1-2 calcium binding sites which induce the conformational change that impacts the N-terminal domain (38) . P300L is in the basic sequence C-terminal to the calcium-binding site and it would be informative to measure the calcium binding capacity of P300L, since it may account for the partial defect in the ATPase activity shown here.
Our previous mouse work showed that GRP94 is an essential gene whose complete ablation is embryonic lethal starting at the stage when IGF-II is first produced, while mice hemizygous for HSP90B1 are phenotypically normal (1) . Thus, it is likely that only hypomorphic variants with activity over 50% of wild type will be found in asymptomatic adult humans. Like other HSP90 family members, GRP94 is a homo-dimeric chaperone with an ATPase cycle that induces folding of its client proteins, including IGFs (reviewed in (53) ). Measurements of nucleotide binding in vitro show saturation at 1 mol per GRP94 dimer, suggesting that perhaps each monomer acts independently of the other (54) . If this is the case, then even heterodimers of P300L-WT GRP94, as found in carriers of the variant, should have lower binding capacity and therefore lower biological activity than wild type, but there is evidently strong evolutionary selection against more severe mutants.
The existence of a minimal activity threshold is supported by data from mouse knockout studies and cell culture gene silencing experiments. Conditional deletion of GRP94 in mouse skeletal muscle is very informative since Cre-mediated deletion in this syncytial tissue is often incomplete, a graded series of expression is created and muscles with 30% less GRP94 than WT have been analyzed (4) . These muscles have a significant reduction in their mass and decreased IGF protein content ( (4) Figures 2 and  6 ), without altered expression of other GH-IGF axis members (4). Therefore, reduced activity of GRP94 leads directly to lower IGF production that in turn diminishes muscle growth in this animal model.
Echoing the animal models, in cell culture, many cell types are known to depend on autocrine or paracrine production of IGF-I and IGF-II to grow and/or avoid apoptosis. Progressive silencing of GRP94 expression using shRNA, or inhibition of its activity using small molecules, also shows that reducing the expression below 50% of wild type level gives rise to progressively lower growth rates and higher susceptibility to stress conditions (9, (55) (56) (57) . Importantly, Eletto et al showed by complementation analysis that cells sense the level of GRP94 activity, not merely its level of expression (13) . Thus, there is solid experimental knowledge that not only predicted the existence of hypomorphic human GRP94 variants, as shown in this work, but also explains the biomedical context of these variants.
The effects of the P300L mutation on GRP94 structure and function are obvious in cell-free and cell culture assays, yet are subtler in the clinical context. Based on our data we would have predicted that a role for GRP94 would have been detected already in the previously published GWAS studies of human growth or aging, yet it has not. In the context of PIGFD, the patient in whom we initially found P300L was heterozygous for the mutation, his mother also carried this mutation and while she was shorter than the population mean (157.5 cm; -0.9 SDs), her short stature was less severe than her child's. This relationship reflects the study of Walenkamp et al where heterozygous carriers of IGF-I mutation exhibited only 1 SD loss of height, while height of homozygotes was -8 SD (58) . Therefore, we surmise that P300L was a contributing factor, rather than sole cause, of the patient's short stature. Age may also play a role; while IGF-I is important for fetal and postnatal growth, IGF-II has been described so far mainly as a prenatal growth factor (59) and production of both factors requires GRP94 activity. Recently, Begemann et al (60) postulated that IGF-II is involved in growth through direct contribution and/or fetal programing. However, lower IGF-II levels delay bone maturation (60) , so that adult height may be less decreased than growth in childhood. Thus, the phenotype may be more severe in neonates and infants (the patient was 18 mos old), with some catch-up growth afterwards resulting in improved height by adulthood. Some catch-up growth may also occur if the loss of IGF-I negative feedback from the GRP94 hypomorph stimulates GH or another factor that can then compensate to some degree for the IGF loss. Similarly, in cohorts such as LGP, where longevity was already shown to be related to IGF-I signaling (61), there was no robust relationship between individuals with P300L GRP94 and lower IGF levels arguably because of a small sample size, heterogeneity of the P300L carriers (males vs. females, younger vs. older) or different mechanisms that block the deleterious effect of the mutation (45) . In contrast, the homogenous HIMS cohort (70 -89 year old Caucasian males) displayed lower IGF-I levels among P300L carriers, consistent with the hypothesis.
There are several potential reasons for the lack of obvious clinical impact of P300L in humans despite the clear effects of P300L in the in vitro experiments. For one, the cell culture and in vitro assays measured the activity of the GRP94 variant in the absence of any other GRP94, while human subjects are mostly heterozygous. It will be interesting to employ genome editing to create a heterozygous GRP94 cell line. The second reason for the in vivo vs. in vitro discrepancy is the nature of the measurements: since GRP94 is a chaperone, it affects a number of proteins expressed in different body systems, so a hypomorphic variant may have multiple effects that do not necessarily augment each other. It should be pointed out in this context, that there is no evidence that any of the IGF-interacting proteins, relevant receptors or transcription factors are affected by GRP94, which is a highly selective chaperone protein. Yet a third reason is that in most GWAS studies the variable assessed may be very much downstream from the primary, biochemical action of the variant GRP94. Even when one measures a more proximal parameter such as IGF-I levels, the measurement is known to be variable, partly because of biological feedback mechanisms that may compensate for the lower IGF-I production. Such mechanisms that counteract the effect of low IGF-I was already suggested by Milman et al (45) , and will be important to explore further.
It is likely that when GRP94 activity is reduced, two types of compensatory mechanisms are activated to restore its folding potential (and thus IGF production). One relates directly to the number of functional GRP94 molecules in the ER; since cells can monitor the total activity, doi: 10.1210/en. press.endocrine.org/journal/endorather than expression of GRP94 (13) , there may be compensatory up-regulation of P300L expression, which we
have not yet detected in cell culture. The second possible compensatory mechanism may be due to the hormonal feedback network between IGF-I and GH. Under normal physiological conditions when IGF-I levels are low, such as in starvation, loss of negative feedback results in a compensatory rise in GH levels (62) (63) (64) . However, since GRP94 is a limiting factor in IGF-I production, compensatory GH-dependent increases in IGF-I production would be possible mostly through higher levels of GRP94 expression in response to GH and more chaperone molecules available for IGF-I folding. This could be determined in future studies. We note that analysis of the GRP94 promoter indicates binding sites of STAT5, a major transcription factor activated through GH binding to its receptor (18, 65) , so increased GH/STAT5 signaling could potentially lead to up-regulation of GRP94. Another consequence of higher GH levels in P300L carriers would be its IGF-independent contributions to linear growth. Evidence shows that GH acts directly on epiphyseal cartilage (66 -71) and mediates 20% of linear growth independently of IGF-I, which could be another regulatory network operating in humans but not recapitulated in cell culture models. P300L is not the only human hypomorphic variant of GRP94. We found a second nonsynonymous SNP (rs34482425) in a European female, which changes Lysine 513 to Asparagine, and this variant also had reduced chaperoning activity towards IGF in the same assay system (Argon et al, unpublished). Thus, variants of GRP94 that affect its expression and/or activity exist in human populations and should be evaluated for their biomedical relevance. It is likely that given the specificity of GRP94 for client proteins like Toll-like receptors (8), immunoglobulins (5) or LDL receptors (I. Braakman, personal communication), hypomorphic GRP94 variants may be discovered also in some patients with immune or cardiovascular dysfunctions.
This work shows that when seeking explanations for defects in human growth, or drug targets that impact growth, the search should not be limited to the candidate genes within the GH/IGF axis described to date. GRP94 is not a direct participant in GH/IGF signaling cascades, nor is it a transcription factor for expression of hormones or their receptors. Rather, it is a chaperone required for hormone protein folding and therefore its secretion. It is remarkable that a housekeeping protein has such a highly selective mode of action toward IGFs [1, [7] [8] [9] . This selectivity, in turn, suggests that the function of the chaperone is important in limiting the bioavailability of IGFs and that this mode of growth regulation should be explored further.
Study approval
PIGFD Consortium: IRB protocol approved by the institutional review board (IRB) of Oregon Health and Science University reference number FWA00000161, IRB00000148.
PIGFD Leiden University Medical Center: Patients were studied under an IRB of the Leiden University Medical Center reference number P07.021.
HIMS: IRB protocol was approved by the Human Research Ethics Committee of the University of Western Australia reference number RA/4/1/5765.
LGP: protocol approved by the IRB of Albert Einstein College of Medicine of Yeshiva University Montefiore Medical Center reference number 1998 -125.
Author contributions
MM conceived the experimental design, performed experiments, analyzed the data and wrote the manuscript. CPH generated population data and performed statistical analysis. DE and SB performed experiments. RR, VH, JMW, HAD, WO, ML, OBP, CTH, BBY, LF, GA and NB acquired and provided population samples and helped analyze the data. AG conceived the experimental design and analyzed data. CPH, VH, JMW, BBY, GA, and AG helped in manuscript preparation. YA designed the project, performed experiments, analyzed the data and wrote the manuscript. All coauthors reviewed the manuscript. HABC project was supported by National Institute on Aging (NIA) Contracts N 01-AG-6 -2101; N01-AG-6 -2103; N01-AG-6 -2106; NIA grant AG-028050, and NINR grant NR-012459.
Disclosure Summary: AG and YA declare that they have interest in intellectual property in growth control, held by CHOP, related to the subject of this work. VH received lecture fees from EMD Serono and sponsored travel from Pfizer, Inc. RGR received payments for consulting or lectures from Ipsen. This potential conflict has been reviewed and managed by OHSU. JMW received payments for consulting or lectures from Pfizer, Sandoz, Versartis, Merck-Serono, OPKO, Teva and Biopartners. WO received unrestricted grant support from Novo Nordisk and Ferring for other studies.
